INTRODUCTION
The human cornea is the transparent outermost surface of the eye and major refractive element of the visual system; its function depends upon its optical clarity. Irreversible loss of optical quality of the cornea due to disease or damage results in permanent vision loss or blindness. The World Health Organization (WHO) estimates that 50 million people worldwide are bilaterally blind, and at least 150 million people have impaired vision in both eyes (1, 2) . Although cataracts are responsible in almost half of the patients with vision loss, corneal damage and disease is the next largest cause. Trachoma, an eye disease caused by the bacterium Chlamydia trachomatis, can lead to corneal inflammation and scarring, and affects roughly 5 million people worldwide. Ulceration and trauma are responsible for an additional 1.5 to 2 million new patients with corneal blindness annually (2) .
The most successful and widely accepted treatment for corneal blindness worldwide is full-thickness replacement of the damaged tissue with a human donor cornea in a procedure known as penetrating keratoplasty (PK). For many conditions where the posterior-most layer (endothelium) is unaffected, both anterior lamellar keratoplasty (ALK) and deep anterior lamellar keratoplasty (DALK), which are procedures that preserve the recipient's endothelium, result in improved graft survival compared to PK.
Regardless of the technique, the fundamental problem with corneal replacement is a severe shortage of donor tissue, resulting in approximately 10 million untreated patients worldwide, and 1.5 million new cases of blindness annually (2) . Additionally, as for all solid organ transplants, donor-derived infection is a serious complication and a leading 4 concern in eye and tissue banking (3) (4) (5) . Pre-transplant screening costs are high and will escalate as more rigorous testing for an increasing number of transmissible pathogens is implemented.
Despite efforts to develop corneal substitutes to alleviate both the shortage and drawbacks of human donor tissues (6) , surgery with allogeneic donor tissue has remained the gold standard for over a century. Recently, however, developments in bioengineered corneal substitutes designed to replace the full or partial thickness of damaged or diseased corneas have been reported (6, 7) . These range from fully synthetic prostheses (eg. keratoprostheses) made from poly-methacrylates, that aim to replace the cornea's refractive function (6, 7) , to tissue-engineered cell-based constructs (8) and hydrogels that also permit the integration of the implant and regeneration of the host tissues (9) (10) (11) . At present, keratoprostheses are the only non-allogeneic option approved for human use.
Although improving and well-retained, keratoprostheses still suffer from the drawbacks of a complex implantation procedure and serious complications, including retroprosthetic membrane formation, calcification, infection, glaucoma, and retinal detachment. Their use is therefore limited to cases in which allogeneic tissue has failed repeatedly or is contraindicated (6, 7, 12) .
Our goal was to adopt a regenerative medicine approach to design a primary alternative to the use of allogeneic tissue for restoring sight by corneal replacement.
Specifically, we proposed to induce regeneration of the damaged corneas by implantation of an acellular matrix that serves to facilitate regeneration by emulating the functions of the highly bioactive natural extracellular matrix (ECM) scaffolding of the cornea.
Because the corneal ECM is largely collagenous (13) , and collagen is a biopolymer that is 5 amenable to modification, we selected collagen as our starting material. The collagen was synthetically crosslinked and moulded into an implantable, biosynthetic corneal substitute (9) (10) (11) . The substitute is cell-free and relies on re-population by host cells to restore corneal function, thereby avoiding the rejection reaction and the need for long-term steroid use. We have successfully implanted a range of these corneal substitutes in animals (9, 11) . With the availability of recombinant collagen (14, 15) , we have developed a class of implants (16) , made from human materials, that alleviate the risk of transmission of infectious agents (such as viruses or prions) inherent in components from animals, while being produced under stringent conditions for quality and safety assurance. We demonstrated safety, biocompatibility, and regenerative potential of lamellar implantation of a recombinant human collagen-based material in mini-pigs (16, 17) . Subsequently we implanted lamellar implants of this biosynthetic material in ten human subjects for keratoconus or corneal scarring and reported the early morphologic and clinical findings (10) . We report here the safety, clinical efficacy, and detailed morphologic and physiologic results from the two-year follow-up of these patients, and compare these results to transplanted human corneal tissue and the response in normal eyes. We specifically evaluated the long term integration and stability of the implanted material, the effectiveness of the surgical procedure, and the degree to which the implants enabled regeneration of endogenous epithelium, nerves, stroma, and tear film.
RESULTS
Ten patients were implanted with 500 µm thick biosynthetic corneal substitutes,
recombinant human collagen. These replacements were optically clear (white light transmittance of 95.1 ± 0.5%), with refractive index 1.35. They were trephined to size, and implanted by anterior lamellar keratoplasty (ALK) with overlying sutures to secure in place ( Fig. 1 ). Sutures were removed after 6.5 ± 3 weeks (mean ± standard deviation; Table 1 ), after which immunosuppressive steroids were stopped while anti-infective medications were continued for another 5.4 ± 3 weeks. Overall, all implanted corneas remained free of major complications (such as stromal edema, neovascularization, or prolonged inflammation), and there were no signs of rejection within the implant or surrounding patient corneal rim at any time during the 24 month follow-up period. There were no patient complaints of pain or discomfort.
After an initial decrease, the thickness of the central cornea in implanted eyes stabilized after the third postoperative month. For the 10 patients, mean central corneal thickness at 24 months (403 ± 109m) was comparable to thickness measured at 3m (404 ± 87m), 6m (420 ± 100m), and 12m (385 ± 90m). At 24 months, the thinnest cornea cataract surgery in the implanted eye with no adverse effects to the implant.
Initial migration of epithelial cells over the implants was rapid, but the coverage was still incomplete by fluorescein staining one month after surgery. Close inspection revealed that epithelial migration over the implant was halted at the crossing points of sutures in the center of the implants ( Fig. 2A and B) . Once sutures were removed, epithelial coverage was completed in all eyes. However, discrete focal areas of haze remained in the regions initially showing delayed epithelial closure, even at 24 months (Fig. 2C , D, see also Supplementary Fig. S1 , S2). Apart from these focal areas of haze, the implants remained transparent. Good overall corneal transparency at 24 months ( Fig.   3 ) was demonstrated by the clear visualization of the retina through the implanted cornea by fundus photography (Fig. 4) . At 24 months, the regenerated epithelium was morphologically normal in all patients, with good stratification and stable attachment (Fig. 5B ). Tear production in the film overlying the epithelium was normal (>15mm in 5 min, without anaesthesia) in 7 of 10 operated and 6 of 10 contralateral eyes (24 months, Regenerating nerves were first noted at the basal epithelium between three and six months after surgery in 6 of 10 implanted corneas. Beaded fibers, which typify the subbasal epithelial nerve plexus, started appearing at 12 months in four patients. A substantial increase in the density of sub-basal nerves was found between 12 to 24 months by IVCM image analysis ( Table 2) .
Nerve function was assessed by measuring corneal sensitivity to mechanical touch with a Cochet-Bonnet aesthesiometer. Some corneal sensitivity returned within the first 12 months after surgery in all 10 eyes (25 ± 14 mm) and improved in all by 24 months (35 ± 17 mm). Sensitivity, however, remained below the response of contralateral eyes with intact innervation that showed an average sensitivity of 60 mm (60 ± 0 mm) corresponding to a normal level (Fig. 6 ). Four of the ten implanted corneas, however, had a sensitivity of 50 mm or better by 24 months.
At 24 months, best spectacle-corrected visual acuity (BSCVA) improved from the preoperative value in 6 patients, remained unchanged in 2 patients, and decreased in 2 patients (Table 1) . BSCVA in the implanted eyes was significantly lower than the values seen in a population of 60 keratoconus patients with penetrating donor tissue transplants two years after surgery (20) (P < 0.001; Mann-Whitney U test) (Table 3) . However, when patients with biosynthetic implants were fitted with rigid, gas-permeable contact lenses, their 24 month BCLVA was comparable to 24 month BSCVA in the transplanted 9 keratoconus population (P = 0.55, Table 3 ). Although all patients who received the biosynthetic implants were contact lens intolerant before surgery (i.e., could not wear contact lenses for more than 2 hours per day without significant irritation), 6 of 7 patients tested could tolerate the rigid contact lenses at the time of the 24 month follow-up.
DISCUSSION
The human cornea is a transparent, hydrated collagenous extracellular matrix (80% water, 13.6% collagen, 0.9% glycosaminoglycans) containing specialized fibroblast-like cells in a stromal layer, sandwiched between an outermost, stratified epithelium and an innermost endothelial layer (13) . Biosynthetic corneal substitutes, based on simple mimics of the natural human extracellular matrix (such as those used in this study), have been tested as microenvironments in which to induce regeneration of tissues and organs that do not regenerate spontaneously (21) . EDC is one of a family of protein crosslinking reagents, the water soluble carbodiimides (WSCs), which have a unique property: the reagents themselves do not become incorporated into the hydrated matrix as part of the final cross-links, so there is no possibility of toxic substances being released into tissues from cross-link breakdown after implantation into patients (22) .
We have reported here that the first ten patients to receive such biosynthetic, collagen-based mimics as partial thickness corneal implants have retained the implant for two years without rejection, peripheral or central vascularization, or infection, and without the need for long-term steroid immunosuppression. In all patients, a stable, morphologically normal epithelium covered the implant and established a viable ocular surface that supported an adequate tear film and restoration of mechanical touch sensitivity. Rapid host-implant integration enabled suture removal much earlier than the typical 4 to 8 months after ALK with human tissue (23, 24) , with implants being stably anchored to the surrounding cornea by recipient stromal cell infiltration at the interfaces.
Additionally, these implants support human nerve regeneration. Nerve regeneration has not been previously possible in corneal prosthetics (6, 7, 12) , nor has it been described in any other alternative corneal substitute tested in humans. Sub-basal epithelial nerves regenerated in nine of ten patients receiving implants and increased in density during the first two years after surgery. In other studies, nerve regeneration has been reported to be slower, occurring as late as 10 years after lamellar keratoplasty in some patients (25) .
Corneal nerves, situated in the anterior two-thirds of the stroma, are transected in ALK and PK procedures. Previous IVCM studies show a complete absence of sub-basal nerves in a high proportion of grafts up to 31 years after PK (26) (27) (28) (29) , and contact aesthesiometry studies have revealed that grafts remain anaesthetic up to 32 years after PK (26, 30, 31) .
Our observations of regenerated sub-basal nerves and return of ocular surface sensitivity within 24 months of surgery suggest that biosynthetic implants may facilitate rapid nerve regeneration. Nerves are essential for the protective aversion response of the cornea to external stimuli, and play a vital role in the maintenance of epithelial health and integrity, in corneal wound healing, and in regulating secretion of the preocular tear film (32) .
In seven patients, discrete focal areas of haze with thinning were observed in areas where the central suture passed over the implant, suggesting that tight retaining sutures overlying the implant delayed central epithelialization of some implants, creating an epithelial defect. This delay likely initiated an early inflammatory response, followed by induction of metalloproteinase enzymes and subsequent localized implant thinning and early stromal invasion by repair fibroblasts. The sutures most likely also accounted for the localized thinning and hence the surface irregularity observed. When this surface irregularity, observed on slit lamp examination ( Corneal nerve function (corneal touch sensitivity) was assessed by Cochet-Bonnet contact aesthesiometry (Cochet-Bonnet aesthesiometer; Luneau Ophthalmologie), where a nylon filament probing the ocular surface was progressively reduced from 60mm
(normal sensitivity) to 10mm (minimal sensitivity) to elicit a response. Filament length at initial response was recorded. Corneal nerve regeneration was assessed with IVCM (17), by manually scanning the basal epithelial plane to visualize sub-basal nerve fiber bundles, first in the central 2 to 3mm and then in the mid-peripheral 3 to 5mm of cornea.
Images were digitally captured at 8 frames/sec during scanning. A single corneal image with the greatest density of central sub-basal nerves was selected from each patient at each follow-up time, for further quantitative analysis. Nerve density (expressed in microns of total nerve length in a digital frame per frame area in mm 2 ) was quantified from images using nerve tracing methodologies to determine total nerve length in a frame, as described in detail elsewhere (17) . Two independent observers traced each image in a blinded manner, and the nerve density for a given image was taken as the mean value. The 95% inter-observer limits of agreement for nerve density were calculated from inter-observer differences at each follow-up time using the Bland-Altman method (18).
Assessment of clinical efficacy
To gauge the efficacy of the biosynthetic implant for vision restoration, the study 
